Comparative inhibitory effect of prenylated coumarins, ferulenol and ferprenin, contained in the 'poisonous chemotype' of *Ferula communis* on mammal liver microsomal VKORC1 activity.

Marie-Sophie Louvet, Gilbert Gault, Sebastien Lefebvre, Florence Popowycz, Manon Boulven, Stéphane Besse, Etienne Benoit, Virginie Lattard, Denis Grancher

► To cite this version:

Marie-Sophie Louvet, Gilbert Gault, Sebastien Lefebvre, Florence Popowycz, Manon Boulven, et al.. Comparative inhibitory effect of prenylated coumarins, ferulenol and ferprenin, contained in the 'poisonous chemotype' of *Ferula communis* on mammal liver microsomal VKORC1 activity.. *Phytochemistry*, 2015, 118 (118), pp.124-130. 10.1016/j.phytochem.2015.08.012 . hal-01577246

HAL Id: hal-01577246

<https://hal.science/hal-01577246>

Submitted on 25 Aug 2017

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Comparative inhibitory effect of prenylated coumarins, ferulenol and ferprenin, contained in the ‘poisonous chemotype’ of *Ferula communis* on mammal liver microsomal VKORC1 activity.

Marie-Sophie LOUVET^{1,*}, Gilbert GAULT^{1,*}, Sébastien LEFEBVRE¹, Florence POPOWYCZ², Manon BOULVEN², Stéphane BESSE¹, Etienne BENOIT¹, Virginie LATTARD¹, Denis GRANCHER¹.

¹ USC 1233 INRA-Vetagro Sup, Veterinary School of Lyon, 1 avenue Bourgelat, 69280 Marcy l’Etoile, France

² Laboratoire de Chimie Organique et Bio-organique, Institut National des Sciences Appliquées (INSA-Lyon), ICBMS-CNRS-UMR 5246, 20 Avenue Albert Einstein, F-69621 Villeurbanne Cedex

Corresponding author: Virginie Lattard
USC 1233 INRA-Vetagro Sup 69280 Marcy l’Etoile, France
Email: virginie.lattard@vetagro-sup.fr; Phone: +33-(0)4 78 87 27 27; Fax: +33-(0)4 78 87 05

16

* Authors contributed equally to this article

ABSTRACT

Two distinguishable chemotypes of *Ferula communis* have been described: the ‘nonpoisonous’ chemotype, containing as main constituents the daucane esters; and the ‘poisonous’ chemotype containing prenylated coumarins, such as ferulenol and ferprenin. Ferulenol and ferprenin are 4-oxygenated molecules such as dicoumarol and warfarin, the first developed antivitamin K molecules. Antivitamin K molecules specifically inhibit VKORC1, an enzyme essential for recycling vitamin K. This latest is involved in the activation of clotting factors II, VII, IX, X. The inhibiting effect of ferulenol on VKORC1 was shown in rat, but not for species exposed to *F. communis* while *in vivo* studies suggest differences between animal susceptibility to ferulenol. The inhibiting effect of ferprenin on VKORC1 was never demonstrated. The aim of this study was to compare the inhibiting effect of both compounds on VKORC1 of different species exposed to *F. communis*. Vitamin K epoxide activity was evaluated for each species from liver microsomes and inhibiting effect of ferulenol and ferprenin was characterized. Ferulenol and ferprenin were shown to be able to inhibit VKORC1 from all analyzed species. Nevertheless, susceptibility to ferulenol and ferprenin presented differences between species, suggesting a different susceptibility to ‘poisonous’ chemotypes of *F. communis*.

Keywords: *Ferula communis* L. (Apiaceae), Ferulenol, Ferprenin, VKORC1, inhibition constant, interspecies variability

Abbreviations : VKOR, Vitamine K epoxide reductase; VKORC1, Vitamin K epoxide reductase complex subunit 1; Vitamin K²O, vitamin K epoxide.

1. INTRODUCTION

Ferula communis L. (Apiaceae) is a perennial and robust weed, native to the Mediterranean basin. Its presence was reported in Syria, Turkey, North Africa, Italy, Sardinia, Portugal, Greece, Croatia, Albania and Palestine (Cauwet Marc, 1981; Infante, 1965). Consumption of *F. communis* L. has been reported to be associated to an hemorrhagic syndrome, also called ferulosis, often fatal in the absence of treatment (Benzaldi, 1988; Cauwet Marc 1990). This intoxication affected almost all mammals and the National Center of Veterinary Toxicology of Lyon (France) diagnosed 28 clinical cases of *Ferula communis* intoxication in cattle, sheep, pig and horse from 1990 to 2013 (Gault et al, 2013). Even man may be affected after an uncontrolled therapeutic use of *Ferula* extract (Cornevin et al, 1887; Lannehoa et al, 1998).

Two distinguishable chemotypes of *F. communis* L. were reported: the ‘non-poisonous’ chemotype and the ‘poisonous’ chemotype associated to the hemorrhagic syndrome (Benkhalti and Lamnaouer, 1994; Sacchetti et al, 2003). Different chemical investigations have reported the presence of daucane esters or drimane ethers, as main constituents in the ‘non-poisonous’ chemotype, according to the geographic area and the presence of prenylated coumarins as main constituents in the ‘poisonous’ chemotype (Appendino et al, 1987; Appendino et al, 2001; Fraigui et al, 2001; Miski and Mabry, 1985; Valle et al, 1987; Rubiolo et al, 2006). Among the prenylated coumarins of the toxic variety, both ferulenol, a 4-hydroxycoumarin derivative, and ferprenin, a pyrane (3,2-c) coumarin derivative (Appendino et al, 1988; Carboni et al, 1964) (Figure 1) could affect blood clotting, as described for other 4-oxygenated coumarin derivatives such as dicoumarol or warfarin, the first developed antivitamin K molecules used in human medicine and as rodenticide for pest control.

4-hydroxycoumarin derivatives, also designed as antivitamin K molecules were reported to specifically inhibit VKORC1, an enzyme encoded by the recent discovered *Vkorc1* gene (Li

et al, 2004; Rost et al, 2004). This enzyme catalyzes the vitamin K 2,3-epoxide reductase activity. This enzymatic activity is essential for recycling vitamin K. The function of VKORC1 is to regenerate vitamin K and vitamin K hydroquinone (K and KH₂) from vitamin K 2,3-epoxide (K>O), a byproduct of the vitamin K-dependent gamma carboxylation reaction (Oldenburg et al, 2008). Inhibition of VKORC1 by 4-hydroxycoumarin derivatives limits the amount of KH₂ available for the carboxylation reaction and results in partially carboxylated vitamin K-dependent blood clotting factors II, VII, IX, X. The specific inhibition of VKORC1 results in a stop of the clotting factors activation leading to a delayed death by hemorrhage. The inhibiting effect of ferulenol on VKORC1 was shown in rat (Gebauer et al.), but not on VKORC1 of species exposed to *F. communis* L..

Previous studies in sheep treated with ferulenol indicated a sharp decreased in activity for several coagulation factors (Tligui et al, 1994). This observation seems to be coherent with the VKORC1-mediated antivitamin K properties of 4-oxygenated coumarins. Nevertheless, another mechanism leading to decrease in coagulation factors was proposed. This decrease was proposed to be due to an impairment of coagulation factors biosynthesis induced by a cytotoxic effect of ferulenol (Monti et al, 2007). Moreover, the toxicity of *F. communis* L. was reported to be not correlated with its contents in ferulenol (Appendino et al, 1988) and another prenylated coumarin, the pyranoferprenin, isolated from *F. communis* L., showed in vivo haemorrhagic activity (Appendino et al, 1988). Nevertheless, the inhibiting effect of ferprenin on VKORC1 was never demonstrated. This study aims to compare the inhibiting effect of ferulenol and ferprenin on VKORC1 from different species in order to demonstrate the mode of action of phytochemicals presumed to be responsible for the toxicity of *F. communis*, plant associated to intoxication that has considerable importance in plant/animal interactions in the Mediterranean countries.

2. RESULTS

2.1.Determination of vitamin K epoxide reductase activity in liver of animal species susceptible to be exposed to *F. communis* L.

In order to evaluate the vitamin K recycling ability of animal species exposed to *F. communis* L., liver microsomes were prepared from cow, calf, goat, lamb, pig, boar and horse. VKOR activity was thus measured at saturating concentration of vitamin K epoxide substrate (i.e., 200 μ M) from the various microsomal fractions. Figure 2 presents the results obtained. All the liver microsomal fractions tested in this study were able to reduce vitamin K epoxide in vitamin K. VKOR activities were found statistically different between species (VKOR activities determined from horse and boar were excluded of the one way analysis of variance). VKOR activity measured in cow liver microsomes was 1.5 to 2-fold higher than that measured in goat, lamb and pig liver.

2.2.Determination of the inhibiting effect of ferulenol and ferprenin on vitamin K epoxide reductase activity

In order to analyze the efficiency of ferulenol and ferprenin as inhibitor of the VKOR activity, susceptibilities to ferulenol and ferprenin were first determined in the presence of calf liver microsomes. The plots of the velocity of the VKOR activity catalysed by calf liver microsomes, versus the substrate concentration in the presence of different concentrations of ferulenol or ferprenin are presented in Figure 3A and 3B, respectively. The inhibiting effects

of ferulenol and ferprenin on VKOR activity catalysed by calf liver microsomes were compared with that obtained in the same conditions with warfarin (Figure 3C).

Ferulenol was able to inhibit VKOR activity. The addition of ferulenol did not modify the apparent K_m ($40.3 \pm 5 \mu M$), while it decreased the apparent V_{max} (Figure 3A). Ferulenol is thus able to inhibit VKOR activity catalysed by calf liver microsomes in a non-competitive manner, as observed with warfarin (Figure 3C). Data were fitted to the Michaelis–Menten model, which takes into account the presence of either competitive, non-competitive, or uncompetitive inhibitor by non-linear regression. A fit was possible when the model that takes into account a non-competitive inhibitor was used only. Finally, K_i towards ferulenol for calf liver microsomes was $0.076 \pm 0.007 \mu M$. K_i towards warfarin obtained in the same conditions was $0.51 \pm 0.04 \mu M$.

Ferprenin was also able to inhibit the VKOR activity catalyzed by calf liver microsomes, but with concentration much higher than those used for inhibition of VKOR activity by ferulenol (Figure 3B). Ferprenin inhibited the VKOR activity in a non-competitive manner, as described for ferulenol. K_i towards ferprenin for calf liver microsomes was $8.2 \pm 0.05 \mu M$. VKOR activity in calf liver microsomes was thus 100-fold more resistant to the action of ferprenin than ferulenol.

2.3.Determination of the species variability of the VKORC1-inhibiting effect of ferulenol

In order to analyse the variation of the efficiency of ferulenol as inhibitor of VKOR activity in the animals exposed to *F. communis* L., K_i values for ferulenol were determined in liver microsomal fractions from cow, goat, lamb, pig, horse and boar and compared to K_i obtained for rat liver microsomes. Ferulenol inhibited the VKOR activity in a non-competitive manner for all the microsomal fractions we analysed (data not shown). The K_i values for ferulenol are

1 in Table 1. They were found statistically different between species (K_i determined from-horse
2 and boar were excluded of the one way analysis of variance). K_i for ferulenol determined in
3
4 cow liver microsomes was 3- to 3.8-fold higher than that measured in calf, goat, lamb, pig and
5
6
7 rat liver.
8
9

10 11 12 13 **2.4.Determination of the species variability of the VKORC1-inhibiting effect of** 14 15 16 **ferprenin**

17
18 In order to analyse the variation of the efficiency of ferprenin as inhibitor of VKOR activity in
19
20 the animals exposed to *F. communis* L., K_i values towards ferprenin were determined in liver
21
22 microsomal fractions from cow, goat, lamb, pig, horse and boar and compared to K_i obtained
23
24 for rat liver microsomes. Ferprenin inhibited the VKOR activity in a non-competitive manner
25
26 for all the microsomal fractions we analysed (data not shown). The K_i values for ferprenin are
27
28 in Table 1. They were found statistically different between species (K_i determined from horse
29
30 and boar were excluded of the one way analysis of variance). K_i for ferprenin determined in
31
32 cow liver microsomes was 3.2-, 6.0-, 2.1-, 1.6- and 9.0-fold higher than that measured in calf
33
34
35 goat, lamb, pig and rat liver.
36
37
38
39
40
41
42

43 44 **2.5.Determination of the species variability of the VKORC1-inhibiting effect of** 45 46 **warfarin**

47
48 In order to compare the efficiency of ferulenol and ferprenin as inhibitor of VKOR activity to
49
50 that of warfarin, K_i for warfarin were determined in liver microsomal fractions from cow,
51
52 goat, lamb, pig, horse and boar. The K_i values are in Table 1. They were found statistically
53
54 different between species (K_i determined in horse and boar were excluded of the one way
55
56 analysis of variance).
57
58
59
60
61
62
63
64
65

3. DISCUSSION

Ferulenol and ferprenin are 4-oxygenated coumarin derivatives synthesized by *F. communis* L.. Coumarin derivatives are known to be potential inhibitor of vitamin K epoxide reductase activity responsible for the recycling of vitamin K, a cofactor essential for the coagulation process. The presence of ferulenol and/or ferprenin was therefore associated with the toxicity of the 'poisonous' chemotype of *F. communis* L. (Appendino et al, 1988; Fraigui et al, 2001). Indeed, the symptomatology associated with *F. communis* L. poisoning is coherent with an anti-VKORC1 activity of ferulenol and/or ferprenin. Nevertheless, few studies allowing to prove the role of ferulenol and/or ferprenin in 'ferulosis' are available. The involvement of ferulenol in the hemorrhagic syndrome was shown by in vivo studies in rats (Aragno et al, 1988, Fraigui et al, 2001, Fraigui et al, 2002, Lamnaouer et al, 1991; Tagliapietra et al, 1989), mice (Fraigui et al, 2001, Fraigui et al, 2002), sheep (Lamnaouer et al, 1990; Otieno et al, 1979; Shlosberg et al, 1985) and lamb (Egber et al, 1998). Nevertheless, the mechanism was not described, except that consumption of ferulenol was associated to decrease in vitamin K-dependent clotting factors. The unique study demonstrating the in vitro inhibiting effect of ferulenol on VKORC1 was performed in rat (Gebauer, 2007), while inter-species differences might exist, since the replacement of one single amino-acid of VKORC1 can lead to enzyme resistant to coumarin derivatives (Grandemange et al, 2010, Hodroge, 2011). The inhibiting effect of ferulenol on VKORC1 of farm animals is still unknown.

In order to determine the underlying mechanism of 'ferulosis', VKOR activity was first analyzed in animal species exposed to *F. communis* L.. VKOR activity has been well characterized in rodents because of the intensive use of coumarin derivatives as rodenticides. In rodents, this activity is exclusively catalyzed by VKORC1 in liver, while this activity might be catalyzed by two enzymes, VKORC1 and VKORC1L1, in other tissues. In farm

1 animals, VKOR activity was until now never studied. Liver microsomes from cow, calf, goat,
2 lamb, pig, boar and horse were used to examine VKOR activity by a DTT-driven VKOR
3 assay, as previously described (Hodroge et al, 2011). This experimental method is a direct
4 approach based on the measurement of the VKORC1 reaction product, the vitamin K. By
5 using this method, VKOR activity was detected in liver of all species analyzed in this study.
6
7 Nevertheless, variations of VKOR activity between species were observed. VKOR activity
8 measured in cattle liver was 1.5- to 2-fold higher than in other species, suggesting inter-
9 species variation in the vitamin K recycling ability. VKOR activity measured in the liver of
10 the different species was efficiently inhibited by warfarin with K_i about 1 to 2 μM , as
11 observed for rats. The inhibition of VKOR activity by warfarin observed in this study is thus
12 totally coherent with an exclusive involvement of VKORC1 in hepatic VKOR activity of the
13 different species exposed to *F. communis* L., as described for rats (Hammed et al, 2013).
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30

31 Since VKOR activity was detected in liver of all animals used in this study, effect of ferulenol
32 and ferprenin on this VKOR activity was analyzed. Ferulenol and ferprenin were found in this
33 study to be able to inhibit VKOR activity in a non-competitive manner, as described for
34 warfarin. The mechanism of inhibition proposed by Silverman (1980) implies the acylation by
35 the 4-oxygenated coumarins of one Cys of the catalytic site of VKORC1 or possibly of a
36 nearby nucleophile amino acid. The proposed mechanism agrees with the irreversible
37 characteristic of the inhibition of the VKOR activity by ferulenol and ferprenin observed in
38 this study.
39
40
41
42
43
44
45
46
47
48
49
50

51 Ferulenol was already reported to inhibit rat VKORC1, with K_i of 0.098 μM (Gebauer, 2007).
52
53 In this study, inhibition of rat VKORC1 by ferulenol was highly similar to that previously
54 reported, with a K_i of 0.04 μM . K_i obtained for ferulenol is 10-fold lesser than that obtained
55 for warfarin (Figure 4). Ferulenol is thus a more potent inhibitor of VKOR activity than
56
57
58
59
60
61
62
63
64
65

warfarin, which is traditionally used in human medicine for patients requiring anticoagulation therapy. K_i obtained for ferulenol is similar to those obtained for the most powerful molecules used as rodenticides such as difethialone or brodifacoum (Hodroge et al, 2011). Ferulenol is also able to inhibit VKORC1 of other species, with K_i similar to that obtained for rat, despite the variations of VKORC1 amino acid sequences between species (i.e., identities between VKORC1 amino acid sequences are comprised between 68 and 84%) (Figure 5). Surprisingly, VKORC1 of cow seems to be more resistant to ferulenol than other VKORC1, while it presents the highest amino acid sequence identity with rat VKORC1. Nevertheless, susceptibility to ferulenol can be qualified to be similar between rat and farm animals. This result is coherent with published studies showing that repeated administration of ferulenol was able to lead to increase in prothrombin time and in reduction of pool of vitamin K-dependent clotting factors (Aragno et al, 1988, Fraigui et al, 2001; Shlosberg et al, 1985; Tagliapietra et al, 1989).

When ferprenin was orally given to rats, Aragno et al (1988) indicates that this compound clearly increases prothrombin time at very high dosage (a minimum of 30 mg.kg^{-1} for 3 days or 10 mg.kg^{-1} for 5 days). Using DTT-driven VKOR assay, ferprenin was also found to be able to inhibit VKOR activity in liver of all species analyzed in this study. Contrary to ferulenol, this ability to inhibit VKOR activity is very surprising, because a free 4-hydroxycoumarin moiety was described to be necessary for anti-VKORC1 activity. Nevertheless, K_i obtained for ferprenin were 2 to 10-fold higher than those obtained for warfarin (Figure 4) and ferulenol is 100- to 500-fold more potent to inhibit VKOR activity than ferprenin, according to the species (Figure 4). Ferprenin is thus a very bad inhibitor of VKOR activity for all species analyzed in this study. The direct effect of this molecule remains surprising because the 4-OH moiety of the coumarinic ring appears to be essential for

1 the interaction with VKORC1 enzyme as shown by Gebauer (2007). The hydrolysis of the
2 pyrane cycle of ferprenin is considered by Aragno et al (1988) as impossible nevertheless it
3
4 should be interesting to evaluate this possibilty either in vivo or even during the microsomal
5
6 DTT-driven VKOR assay. Contrary to ferulenol, ferprenin seems to be more subject to inter-
7
8 species variation. Indeed, in rats, Ki obtained for ferprenin is about 1 μ M, while in cow Ki is
9
10 about 15 μ M. Therefore, ferprenin could be much more potent to inhibit VKORC1 in rat than
11
12 in cow. Moreover, demonstration of in vivo effect of ferprenin is only available in rat (Aragno
13
14 et al, 1988).
15
16
17
18
19
20
21

22 4. CONCLUSIONS

23
24 Ferulenol, and in a lesser extent, ferprenin are thus certainly both responsible for the
25
26 hemorrhagic syndrome. Neverteheless, *F. communis* also contain COX-inhibiting
27
28 polyacetylenes that could synergistically contribute to the poisonous property of the plant
29
30 (Appendino et al, 1993). Toxicity of ferulenol and ferprenin is also driven by
31
32 pharmacokinetics and inter-species variations in pharmacokinetics of these compounds. Few
33
34 studies about pharmacokinetics of these compounds are available. Published results argue for
35
36 a high metabolic clearance of ferulenol. Indeed, while Ki obtained for ferulenol is lower than
37
38 that obtained for warfarin, the dosage of ferulenol necessary to lead to an increase in
39
40 prothrombin time in rat appears to be about 10-fold higher than that used for warfarin (Aragno
41
42 et al, 1988). The hemorrhagic effect is strictly dependent on the continuous presence of high
43
44 concentration of VKORC1 inhibitor in the liver. Indeed, few hours without this inhibition will
45
46 be enough to fully restore the pool of clotting factors. Considering a high metabolic clearance,
47
48 the toxicity of such compounds will directly depend on the pattern of administration. Frequent
49
50 repeated dosages are strictly necessary to maintain the inhibiting concentration in the liver.
51
52
53
54
55
56
57
58
59 Ruminant administration can be considered as a continuous delivery of ferulenol even if the
60
61
62
63
64
65

consumption of *F. communis* L. is not continuous as observed in sheep after oral administration of repeated administration of ferulenol. (Tligui et al, 1994). The detection of ferulenol in 'non-poisonous' chemotypes of *F. communis* L. (Rubiolo et al, 2006) questioned the only responsibility of ferulenol and ferprenin in the hemorrhagic syndrome. Nevertheless, ferulenol and ferprenin are found to be present in far smaller amounts in 'non-poisonous' chemotypes of *F. communis* L. than in 'poisonous' chemotypes. The consumption of these chemotypes does not allow to reach sufficient hepatic concentration leading to complete inhibition of VKOR activity in liver and thus in a stop of the vitamin K-dependent clotting factors activation.

5. MATERIALS AND METHODS

5.1. Animals

Livers from lamb, cow, horse, goat, pig and calf were collected from the slaughterhouse at Saint Romain de Popey (France) under special authorization of the veterinary services and after veterinary health examination. Male OFA-Sprague Dawley rats (200g) were obtained from a commercial breeder (Charles River, L'Arbresles, France) and acclimated for a minimal period of 5 days. Rat food and water were available ad libitum. The rats were killed by decapitation. The boar was hunted and the liver was removed according to the regulations. All samples were immediately frozen at - 80° C. Three different animals of each species were sampled excepted in horse and boar where only one sample could be obtained.

5.2. Chemical syntheses

Vitamin K1 (Phylloquinone) was converted into vitamin K1OX according to Tishler et al (1940). Ferulenol was synthesized accordingly to Gebauer et al (2007). Oxidation of

trans,trans-farnesol with PDC afforded farnesal in 87% yield (Hu et al, 2004). Ferprenin was obtained by reaction of 4-hydroxycoumarin with 2 equivalents of trans,trans-farnesal in water at 80°C, in a Knoevenagel / electrocyclization tandem mechanism (Jung et al, 2010) (SI 1).

5.3. Microsomes preparation

Liver microsomes were prepared by differential centrifugations as previously described (Moroni et al, 1995). Protein concentrations were determined by the method of Bradford (1976) using serum albumin as a standard.

5.4. Vitamin K epoxide reductase activity

Microsomal vitamin K epoxide reductase (VKOR) activity was assayed according to a modified protocol previously described by Thijssen (1987), Thijssen and Baars (1989) and Misenheimer and Suttie (1990). Briefly, standard reactions were performed in 200 mM Hepes buffer (pH 7.4) containing 150 mM KCl, 1 mM dithiothreitol, 1 mg of total proteins. The reaction was started by the addition of vitaminK₂O solution in 1% Triton X-100. After incubation at 37°C for 30 min, the reaction was stopped by adding 4 mL of iced 1:1 isopropanol/hexane solution. After centrifugation at 5000g for 10 min, the hexane layer was removed and dried under nitrogen. The dry residue was immediately dissolved in 0.2 mL of isopropanol and reaction product was analyzed by UV-HPLC.

5.5. Vitamin K1 measurement

Vitamin K1 was measured by high performance liquid chromatography (HPLC). The HPLC chain consisted of an autosampler (Merck AS-2000A), an intelligent pump (Merck L-6200A), a UV-VIS detector (Merck L-4250) and an enregistorr (Merck SS420X). Separation was achieved on a C8, 5 µm, 4,6 x 150 mm analytical column (Sunfire, Irl). The flow rate of the

mobile phase (methanol 96%, water 4%, formic acid 1%) was 0.8 mL/min. The column temperature was 40°C. Detection was performed at 248 nm.

5.6.Kinetics

Kinetic parameters (K_m and V_{max}) were obtained from at least two separate experiments after the addition of increasing amounts of vitamin K₂O (0.003 to 0.2 mM) to the standard reaction. The estimation of the kinetic parameters was achieved by the incubation of at least 9 different concentrations of vitamin K₂O. Incubations were performed in duplicate. Data were fitted by nonlinear regression to the Michaelis-Menten model using the curve fitter program of Sigmaplot 9.0TM software.

In order to evaluate the inhibiting effect of various molecules (warfarin, ferulenol and ferprenin) (figure 1) on VKOR activity, inhibition parameters (K_i) were determined after addition of various concentrations of molecules to the standard reaction. Inhibition parameters were first assessed with 4 different concentrations (0.01, 1, 10 and 30 μ M) and further more precisely determined using concentrations from about 0.05 to $20 \times K_i$. Data were fitted by non-linear regression to the non-competitive inhibition model using Sigmaplot 9.0TM software.

ACKNOWLEDGEMENTS

This work was supported by grants ISI n°I1301001W “NEORAMUS” from Bpi France.

LEGENDS OF FIGURES

Figure 1: Chemical structures of warfarin (A), Ferulenol (B) and Ferprenin (C)

Figure 2 : Vitamin K epoxide reductase activity in animals exposed to *F. communis*. L.

Enzyme activity was evaluated in the presence of 200 μ M of KOX and 1 mg of liver

microsomal proteins. Each data point represents the mean $\pm$ SD of three individual determinations.

Figure 3 : Plots of vitamin K epoxide reductase activity versus vitamin K > O (6.25–200 μ M), in the presence of various concentrations of ferulenol (A) or ferprenin (B) or warfarin (C) incubated with calf liver microsomes.

Figure 4 : Comparison of the inhibition effect of warfarin, ferulenol and ferprenin using various liver microsomes. A/ Inhibition effect of ferulenol or ferprenin compared to warfarin, B/ Inhibition effect of Ferulenol compared to ferprenin.

Figure 5 : Multiple sequence alignment of VKORC1 enzymes of animals exposed to *F. communis* L. The active site is indicated by the box.

SI 1 : Ferprenin synthesis

REFERENCES

Appendino, G., Tagliapietra, S., Gariboldi, P., Nano, G.M., Picci, V., 1987. ω -Oxygenated prenylated coumarin from *Ferula communis*. *Phytochemistry*. 27, 3619-3624.

Appendino, G., Tagliapietra, S., Nano, G.M., Picci, V., 1988. Ferprenin, a prenylated coumarin from *Ferula communis*. *Phytochemistry*. 27, 944-946.

Appendino, G., Tagliapietra, S., Nano, G.M., Picci, V., 1993. An Antiplatelet Acetylene from the Leaves of *Ferula communis*. *Fitoterapia*. 64, 179.

Appendino, G., Cravotto, G.C., Sterner, O., Ballero, M., 2001. Oxygenated sesquiterpenoids from a non poisonous sardinian chemotype of giant fennel (*Ferula communis*). *J. Nat. Prod.* 64, 393-395.

Aragno, M., Tagliapietra, S., Nano, G.M., Ugazio, G., 1988. Experimental studies on the toxicity of *Ferula communis* in the rat. *Res. Commun. Chem. Pathol. Pharmacol.* 59, 399-402.

Arnoldi, L., Ballero, M., Fuzzati, N., Maxia, A., Mercalli, E., Pagni, L., 2004. HPLC-DAD-MS identification of bioactive secondary metabolites from *Ferula communis* roots. *Fitoterapia*. 75, 342-354.

Benkhalti, F., Lamnaouer, D., 1994. Activité anticoagulante de quelques principes isolés de *Ferula communis* L. Actes du 1^{er} colloque international « La pharmacopée Arabo-islamique, Hier et Aujourd'hui ». 215-220.

1
2 Bradford, M.M., 1976. A rapid and sensitive method for the quantitation of microgram
3
4 quantities of proteins utilizing the principle of protein dye binding. Nature. 227, 248-254.
5
6
7

8
9 Carboni, S., Malaguzi, V., Marsili, A., 1964. Ferulenol, a new coumarin derivative
10
11 from *Ferula communis*. Tetrahedron Lett. 38, 2783-2786.
12
13
14
15

16
17 Cauwet-Marc, A.M., 1990. Le férulisme. Rev. Res. Amélior. Agr. Milieu Aride. 2, 1-7.
18
19
20
21

22
23 Cauwet-Marc, A.M., 1981. Le complexe *Ferula communis* L. dans ses populations du sud de
24
25 la France et de la Corse. Biologie Ecologie Méditerranéenne. 8, 101-118.
26
27

28
29
30 Cauwet-Marc, A.M., 1981. Le genre *Ferula communis* L. sur le pourtour du bassin
31
32 méditerranéen. 106^{ème} congrès des Sociétés savantes, Perpignan. 22, 77-87.
33
34
35

36
37 Cornevin, C., 1887. Des plantes vénéneuses et des empoisonnements qu'elles déterminent.
38
39 Librairie de Firmin-Didot et Cie, Paris, France, pp. 380-396.
40
41
42

43
44
45 Egber, A., Perevolotsky, A., Yonatan, R., Shlosberg, A., Belaich, M., Landau, S., 1998.
46
47 Creating aversion to giant fennel (*Ferula communis*) in weaned orphaned lambs. Applied
48
49 Animal Behaviour Science. 61, 51-62.
50
51

52
53
54 Fraigui, O., Lamnaouer, D., Faouzi, M.Y., 2001. Acute toxicity of ferulenol, a 4-
55
56 hydroxycoumarin isolated from *Ferula communis* L. Vet. Hum. Toxicol. 44, 5-7.
57
58
59
60
61

1 Gault, G., Riera, M., Berny, P., Benoit, E. and Grancher, D., 2015. Giant fennel (*Ferula*
2 *communis* L.) intoxications in livestock in France. Proceedings of the 9th Congress of the
3 International Society of Poisonous plants (ISOPP). Hohhot (PR China). 15, 95-99.
4
5
6
7

8
9 Gebauer, M., 2007. Synthesis and structure–activity relationships of novel warfarin
10 derivatives. *Bioorg. Med. Chem.* 15, 2414–2420
11
12
13
14
15

16 Grandemange, A., Lasseur, R., Longin-Sauvageon, C., Benoit, E. and Berny, P., 2010.
17 Distribution of VKORC1 single nucleotid polymorphism in wild *Rattus norvegicus* in France.
18 *Pest. Manag. Sci.* 66, 270-276.
19
20
21
22
23

24
25 Hammed, A., Matagrín, B., Spohn, G., Prouillac, C., Benoit, E., Lattard, V., 2013.
26 VKORC1L1, an enzyme rescuing the VKOR activity in some extrahepatic tissues during
27 anticoagulation therapy. *J Biol Chem.* 288, 28733-28742.
28
29
30
31
32
33

34
35 Hodroge, A., Longin-Sauvageon, C., Fourel, I., Benoit, E., Lattard, V., 2011 Biochemical
36 characterization of spontaneous mutants of rat VKORC1 involved in the resistance to
37 antivitamin K anticoagulants. *Arch. Biochem. Biophys.* 515,14-20.
38
39
40
41
42
43

44
45 Hu, H., Harrison, T.J., Wilson, P.D., 2004. A modular and concise total synthesis of (±)-
46 Daurichromenic acid and analogues. *J. Org. Chem.* 69, 3782-3786.
47
48
49
50
51

52
53 Infante, M., 1965. Intoxicacion por *Ferula communis* L. (intoxication by *Ferula communis*
54 L.). *Archivos de zootecnia.* 14, 25-54.
55
56
57
58
59
60
61
62
63
64
65

1 Jung, E.J., Park, B.H., Lee, Y. R., 2010. Environmentally benign, one-pot synthesis of pyrans
2 by domino Knoevenagel / 6π -electrocyclization in water and application to natural products.
3
4 Green Chem. 12, 2003-2011.
5
6
7
8

9 Lamnaouer, D., Fraigui, O. and Abadome, F., 1991. Toxicité et activité anticoagulante de
10 quelques constituants de *Ferula communis* L. chez le rat. Al Biruniya, Revue Marocaine de
11 Pharmacie, Rabat. 7, 135-142.
12
13
14
15
16

17
18
19
20 Lamnaouer, D., Omari, M., Mounir, A., El-Alouani, M., 1990. Activité anticoagulante de
21 *Ferula communis* L. chez le mouton. Maghreb Vétérinaire. 5, 5-10.
22
23
24
25

26
27 Lannehoa, Y., Harry, P., Michau, C., Fareta, A. and Merad, R., 1998. Anal bleeding due to
28 hypovitamin K caused by ingesting « fassoukh ». Presse médicale, 31, 1579.
29
30
31
32

33
34 Li, T., Chang, C.Y., Jin, D.Y., Lin, P.J., Khvorova. A., Stafford, D.W., 2004. Identification of
35 the gene for vitamin K epoxide reductase. Nature. 427, 541-544.
36
37
38
39
40

41 Misenheimer, T.M., Suttie, J.W., 1990. Warfarin resistance in a chicago strain of rats.
42 Biochem. Pharmacol. 40, 2079-2084.
43
44
45
46

47
48
49 Miski, M., Mabry, T., 1985. Daucane esters from *ferula communis* subsp. *Communis*.
50 Phytochemistry. 24, 1735-1741.
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 Monti, M., Pinotti, M., Appendino, G., Dallocchio, F., Bellini, T., Antognoni, F., Poli, F.,
2 Bernardi, F., 2007. Characterization of anti-coagulant properties of prenylated coumarin
3 ferulenol. *Biochem. Biophys. Acta.* 1770, 1437-1440.
4
5
6
7
8
9
10 Moroni, C., Longin-Sauvageon, C., Benoit, E., 1995. The Flavin-containing monooxygenase
11 in rat liver : evidence for the expression of a second form different from FMO1. *Biochem.*
12
13
14
15
16
17
18
19 Oldenburg, J., Marinova, M., Müller-Reible, C., Watzka, M., 2008. The vitamin K cycle.
20
21
22
23
24
25
26
27 Otieno, P., 1979. Toxicity of *Ferula Communis* in sheep and goats. Annual report of the
28
29
30
31
32
33
34
35 Rost, S., Fregin, A., Ivaskevicius, V., Conzelmann, E., Hörtnagel, K., Pelz, H.J., Lappegard,
36
37
38
39
40
41
42
43
44
45
46
47 Rubiolo, P., Matteodo, M., Riccio, G., Ballero, M., Christen, P., Fleury-Souverain, S.,
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Sacchetti, G., Appendino, G., Ballero, M., Loy, C., Poli, F., 2003. Vittae fluorescence as a tool to differentiate between poisonous and non poisonous populations of giant fennel (*Ferula communis*) of the island Sardinia (Italy). *Biochem. Syst. Ecol.* 31, 527–534.

Shlosberg, A. and Egyed, M.N., 1985. Experimental *Ferula communis* (giant fennel) toxicosis in sheep. *Zentralblatt für Veterinärmedizin Reihe A.* 32, 778-784.

Silverman, R.B., 1980. A Model for a "Molecular Mechanism of Anticoagulant Activity of 3-Substituted-4-Hydroxycoumarins. *J. Am. Chem. Soc.* 102, 5421–5423.

Tagliapietra, S., Aragno, M., Ugazio, G., Nano, G.M., 1989. Experimental studies on the toxicity of some compounds isolated from *Ferula communis* in the rat. *Res. Commun. Chem. Pathol. Pharmacol.* 66, 333-336.

Thijssen, H., 1987. Vitamin K epoxide reductase of Scottish resistance genes is not irreversibly blocked by warfarin. *Biochem. Pharmacol.* 36, 2753-2757.

Thijssen, H., Baars, L., 1989. Microsomal warfarin binding and vitamin K 2,3-epoxide reductase. *Biochem. Pharmacol.* 38, 1115-1120.

Tishler, M., Fieser, L., Wendler, N., 1940. Hydro, oxydo and other derivatives of vitamin K1 related compounds. *J. Am. Chem. Soc.* 62, 2866-2871.

1 Tligui, N., Ruth, G.R., Felice L.J., 1994. Plasma ferulenol concentration and activity of
2 clotting factors in sheep with *Ferula communis* variety *brevifolia* intoxication. *Am. J. Vet.*
3
4
5 Res. 55, 1564–1569.
6
7

8
9 Valle, M.G., Appendino, G., Nano, G.M., Picci, V., 1987. Prenylated coumarin and
10
11
12 sesquiterpenoids from *Ferula communis*. *Phytochemistry*. 26, 253–256.
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Table 1 : *K_i* values of ferulenol, ferprenin and warfarin determined in various liver microsomes.

Species	Ki for Ferulenol (μM)	Ki for Ferprenin (μM)	Ki for Warfarin (μM)
Cow	0.13 ± 0.06	16.6 ± 1.2	2.3 ± 0.4
Calf	0.04 ± 0.01	5.2 ± 1.4	2.5 ± 0.1
Goat	0.04 ± 0.02	2.8 ± 1.4	1.6 ± 1.3
Lamb	0.03 ± 0.01	8.0 ± 4.0	0.8 ± 0.2
Pig	0.04 ± 0.01	10.3 ± 1.9	1.2 ± 0.2
Boar	0.08 ± 0.02	3.7 ± 0.6	0.8 ± 0.1
Horse	0.04 ± 0.01	16.3 ± 2.1	1.3 ± 0.3
Rat	0.03 ± 0.01	1.9 ± 0.4	0.5 ± 0.1

Figure

[Click here to download high resolution image](#)

Figure 1

Figure 2

Figure 3

Figure
[Click here to download high resolution image](#)

Figure 4

Figure
[Click here to download high resolution image](#)

Figure 5

Supplementary Information

[Click here to download Supplementary Information: SI1.tif](#)